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ABSTRACT
Objective: The aim was to study the vision-related quality of life (QOL) for diabetic retinopathy (DR) among patients with Type 2 diabetes and to 
assess the direct medical cost of different treatment modalities.
Methods: It was based on an individual-based analysis of QOL before and after the treatment for DR. The main objective of the study was to compare 
QOL between patients based on the different treatment modalities using vision function questionnaire (VFQ)-25, to evaluate the direct medical cost 
for DR patients undergoing different treatment modalities and to compare the cost and QOL of different treatment modalities in samples with non-
proliferative DR (NPDR)/proliferative diabetic retinopathy (PDR) macular edema. The population included were patients with Type 2 diabetes with 
NPDR, with clinically significant macular edema and PDR, patients diagnosed to have diabetes above 5-year duration, adult patients, ocular pain 
those who are on regular follow-up and those who are willing to be a part of study. A total of 256 patients were selected out, of which 141 patients 
were satisfied the study criteria and participated in the study. Data relevant to the voice-related QOL study were obtained and recorded using VFQ-25 
questionnaire. Other data relevant to the study were obtained and recorded in a semistructured data collection form by interviewing the patient or 
their caregivers and by direct examination of patient’s medical record. Expenditure was calculated in Indian Rupees.
Results: After comparing the baseline QOL with QOL after treatment, it was found that the overall QOL of the study samples in accordance with the 
treatment undergone was found to be improved. The overall QOL had improved after the treatment for all samples and major improvement was seen 
on dependency, social functioning (SF), and mental health (MH).
Conclusion: The overall QOL had improved after the treatment for all samples and major improvement were seen on dependency, SF, and MH. In 
conclusion, the study analyzed that intravitreal bevacizumab therapy is the cheapest one and with the comparatively same clinical outcome when 
compared with intravitreal ranibizumab therapy for macular edema cases in patients with NPDR and PDR.
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INTRODUCTION
Diabetes mellitus (DM) is a chronic disorder with estimated prevalence 
rate of 6.4% in total population [1]. DM is a group of metabolic disorders 
characterized by hyperglycemia. It is associated with abnormalities in 
carbohydrate, fat, and protein metabolism. Type 1 is insulin-dependent 
diabetes which is an autoimmune disorder developing in childhood or 
early adulthood. Type 2 which is non-insulin dependent is characterized 
by insulin resistance and a relative lack of insulin secretion. Patients 
with Type 2 diabetes are more prone to develop micro- and macro-
vascular complications that lead to damage of end organs such as 
kidneys, brain, and eyes, affect the direct and indirect cost and quality 
of life (QOL) [2]. Lack of education of the disease and its comorbidities 
is the leading cause for complications in any disease [3]. A study was 
conducted on QOL assessment in diabetic retinopathy (DR) among 
the patients with Type 2 diabetes before and after treatment. There 
is evidence that retinopathy begins to develop at least 7 years before 
being clinically diagnosed [4,5]. DR is a sight-threatening and chronic 
ocular disorder that eventually develops to some degree in nearly 
all people with diabetes. DR is an ocular manifestation of systemic 
disease which affects up to 80% of all patients who have had diabetes 
for 10 years or more [6]. Despite these intimidating statistics, research 
indicates that at least 90% of these new cases could be reduced if there 
was proper and vigilant treatment and monitoring of eyes [7]. After 
10 years of DM, blindness was 1.8, 4.0, and 4.8% in Type 1, insulin-
treated Type 2, and non-insulin treated Type 2 patients [8]. The main 
objective of the study was to compare QOL between patients based on 
the different treatment modalities using vision function questionnaire 
(VFQ). The patients visiting the Ophthalmology Department of Amrita 
Institute of Medical Science were selected depending on the inclusion 
and exclusion criteria. Data relevant to the voice-related QOL (VRQOL) 
study were obtained and recorded using VFQ 25 questionnaire. 
Other data relevant to the study were obtained and recorded in a 
semistructured data collection form by interviewing the patient or 
their caregivers and by direct examination of patient’s medical record.
METHODS
Design of study
This was a non-experimental (observational), prospective study.
Settings
This study was carried out at the Outpatient Department of 
Ophthalmology of Amrita Institute of Medical Sciences (AIMS), Kochi. 
It is a 1450-bedded tertiary care, teaching, and super specialty referral 
hospital located in a huge campus at Elamakkara in Cochin. Facilities 
at AIMS include 210 outfitted intensive care beds and 25 operating 
theaters.
Study population
The study included patients visiting the ophthalmology ocular pain 
(OP) Department with DR and who satisfy the inclusion and exclusion 
criteria.
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Inclusion criteria (Figs. 1-7)
•	 Patients	with	Type	2	diabetes	with	non-proliferative	DR	(NPDR)	
with	clinically	significant	macular	edema	(CSME)	and	proliferative	





Exclusion criteria (Figs. 1-7)
•	 Patients	with	Type	1	diabetes,	gestational	diabetes,	and	drug-induced	







A total of 256 patients were diagnosed to have Type 2 DR who visited 
the ophthalmology department during the study period. From that, 
141 patients were satisfied the study criteria and participated in the 
study.
Date collection
Data relevant to the VRQOL study were obtained and recorded using 
VFQ 25 questionnaire. Other data relevant to the study were obtained 
and recorded in a semistructured data collection form by interviewing 






An observational, prospective study was carried out on patients who were 
diagnosed to have DR under the Department of Ophthalmology of AIMS, 
Kochi, from March 1st 2011 to August 31st 2011. The aim was to assess 
the outcome of the treatment. The aim was to assess the outcome of the 
treatment that the patients have undergone according to the severity of 
the disease so as to study to what extend it had an impact on their QOL 
and to calculate the direct medical cost involved in the treatment process. 
It was based on an individual-based analysis of QOL before and after 
treatment for DR. Data were collected using a VFQ 25 questionnaire and 
a semistructured data collection forms and all information relevant to 
the study was entered by interviewing the patient and analyzing the case 
record. Direct medical cost was collected includes practitioner consultation 
fees, acquisition cost of medicines, different types of procedure costs, and 
the cost of different laboratory investigations. Expenditure in this study 
was calculated in accordance with Indian rupees.
Fig. 1: Graphical representation of overall quality of life scoring of 
samples before and after treatment
Fig. 2: Comparison of quality of life before and after treatment 
based on intravitreal ranibizumab therapy
Fig. 3: Comparison of quality of life before and after treatment 
based on intravitreal bevacizumab therapy
Fig. 4: Comparison of quality of life before and after treatment 
based on focal laser therapy
Table 1: Types of DR
Classification of DR Frequency (%) Total (%)
Female Male
NPDR with CSME 12 (7.7) 16 (10.3) 28 (18)
PDR without CSME 37 (23.8) 67 (43.4) 104 (67.0)
PDR with CSME 3 (1.9) 6 (3.8) 9 (5.8)
NPDR: Non-proliferative diabetic retinopathy, CSME: Clinically significant 
macular edema, PDR: Proliferative diabetic retinopathy
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RESULTS
Age distribution of the patients in the study group
Majority of the patients were in the age group of 60-64. The youngest 
patient in the study population was 35-year-old and oldest was 
80-year-old.
Gender distribution
Out of 256 patients with DR, 141 patients were satisfied the study 
criteria. Among that, 63.12% were male and 36.87% were female.
Direct medical cost
Drugs used to cure macular edema were bevacizumab and ranibizumab 
and it cost Rs. 6800/- and Rs. 75,000/-. The drugs given for symptomatic 
relief were nepafenac (nevanac) which cost Rs. 175/-, moxifloxacin eye 
drops (milflox) Rs. 70/-, vigamox Rs. 195/-, prednisolone acetate eye 
drops Rs. 95/-, paracetamol (Dolo 650 mg) Rs. 2/tablet. The diagnosis is 
done by slit-lamp biomicroscopy which cost Rs. 75/-, optical coherence 
which cost Rs. 1250/-, and fundus fluorescein angiography which cost 
Rs.1000/-. Pan retinal photocoagulation laser therapy (PRP) and focal 
laser therapy cost Rs. 1000/- and Rs. 2000/-, respectively. Consultation 
fee costs Rs. 130/- and Rs. 180/- without and with appointment, 
respectively.
By evaluating the average of total direct medical cost, Rs. 79,040.00 
and Rs. 10,804.92 cost for PRP laser+ranibizumab therapy and PRP 
laser+bivacizumab therapy, respectively. The average direct medical 
cost for focal laser+intravitreal ranibizumab therapy and focal 
laser+intravitreal bivacizumab therapy was estimated as Rs. 80,031.75 
and Rs. 11,383.18, respectively.
QOL
A total of 141 patients were interviewed using National Eye Institute 
VFQ-25 (with subscales) before and after treatment. After comparing 
the baseline QOL with QOL after treatment, it was found that the overall 
QOL of the study samples in accordance with the treatment undergone 
was found to be improved.
The VFQ 25 contains different domains such as general health, general 
vision, OP, near activities, distance activities, social functioning, mental 
health, role difficulties, de-dependence, color vision, peripheral vision, 
and driving.
DISCUSSION
DR is a sight-threatening and chronic ocular disorder that eventually 
develops to some degree in nearly all people with diabetes. An 
observational, prospective study was carried out on patients who were 
diagnosed to have DR. The study conducted by Ossama and El Haddad 
et al. reported that higher percentage of samples was having NPDR 
than PDR. According to the study, 30% of samples were within the age 
group of (60-64), 16% within (55-59), 14% within (50-54), 13% within 
(65-69), and 12% within (45-49). A study conducted by Rasmieh et al. 
in 1000 DR patients with Type 2 DM. About 40% of the patients were 
within the age group of 56-65 years of age [9]. When the samples were 
categorized based on the treatment undergone according to their grade 
of DR, it was found that 67% undergone PRP laser, 10.3% undergone 
intravitreal bevacizumab therapy, 3.8% undergone intravitreal 
ranibizumab therapy, and 9.6%undergone focal laser therapy. The 
present study shows change in QOL after the treatment which indicates 
that there was an improvement in the overall QOL among samples in 
accordance with the treatment modalities. When compared the cost 
of treatment with the representative QOL, it showed that there is high 
variation in terms of money value between the intravitreal injections of 
bevacizumab and ranibizumab. Though the efficacy was comparatively 
similar ranibizumab is much safer than bevacizumab, because later 
one is an off - label drug and required reconstitution since 0.05 ml is 
required for the treatment of macular edema form the 4 ml vials. A study 
conducted by rich, Simó et al. (2009) [10] on the safety and efficacy 
of intravitreal bevacizumab reported that intravitreal bevacizumab is 
Fig. 6: Comparison of quality of life before and after treatment 
based on photocoagulation laser therapy laser+bevacizumab 
therapy [6]
Fig. 5: Comparison of quality of life before and after treatment 
based on photocoagulation laser therapy
Table 2: Treatment undergone
Types of DR Treatment undergone Overall QOL score p value
Before treatment After treatment Change in QOL
NPDR with CSME Intravitreal bevacizumab therapy+focal laser 73.69 93.19 19.50 0.001
Intravitreal ranibizumab therapy+focal therapy 70.92 93.70 22.78 0.001
Focal laser therapy 73.83 93.04 19.21 0.001
PDR without CSME PRP 71.13 85.98 14.85 0.001
PDR with CSME PRP laser+bevacizumab therapy 68.79 86.68 17.89 0.001
PRP laser+ranibizumab therapy 67.47 87.03 19.56 0.001
NPDR: Non-proliferative diabetic retinopathy, QOL: Quality of life, CSME: Clinically significant macular edema, PDR: Proliferative diabetic retinopathy, PRP: Pan retinal 
photocoagulation
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a cost-effective therapy for the treatment of neovascular age-related 
macular edema, but the long-term safety and efficacy remain unknown. 
The findings suggest that treatment regimen, level of glycemic control, 
and the presence of complications are associated with QOL [11].
CONCLUSION
The study was conducted on the vision-related QOL for DR among 
patients with Type 2 diabetes and to assess the direct medical cost of 
different treatment modalities. A total of 141 cases of Type 2 DM having 
DR were selected during the study period of which males were more 
when compared to females. Among the samples collected, it is shown 
that higher prevalence of disease was associated with PDR cases. 
Majority patients were with >60 years of age out of the total sample. 
Out of the 141 patients, 88.6% were having above 10 years duration 
of DM. Direct medical cost study showed a higher cost of therapy for 
intravitreal ranibizumab injection when compared to intravitreal 
bevacizumab therapy. There was an improvement in their QOL after the 
treatment and the change in QOL between the study samples who had 
Fig. 7: Comparison of quality of life before and after treatment 
based on photocoagulation laser therapy laser+ranibizumab 
therapy
undergone intravitreal injections were only 0.7. The overall QOL had 
improved after the treatment for all samples and major improvement 
was seen on dependency, social functioning, and mental health. In 
conclusion, the study analyzes that intravitreal bevacizumab therapy 
is the cheapest one and with the comparatively same clinical outcome 
when compared with intravitreal ranibizumab therapy for macular 
edema cases in patients with NPDR and PDR.
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